Mondosanità reported on Thursday that immunotherapy can replace two cycles of chemotherapy in treating high-risk pediatric leukemia, with relapses nearly halved compared to standard treatment. The Italian health outlet described the approach as a shift in how the disease is managed in children.
The reporting focuses on acute lymphoblastic leukemia, a blood cancer that affects children. According to the coverage, immunotherapy has been positioned as an alternative to part of the chemotherapy regimen rather than an addition to it, reducing the number of chemo rounds patients receive.
Mondosanità's headline stated that relapses dropped by almost half when immunotherapy took the place of two chemotherapy cycles. The outlet did not provide the underlying trial data or patient numbers in the summary available.
Other Italian outlets covered the same development. ANSA reported that immunotherapy halves recurrences in pediatric acute leukemia, while Il Sole 24 ORE framed the news around high-risk cases specifically. La Repubblica reported that immunotherapy can lead to recovery in up to 80 percent of cases of lymphoblastic leukemia.
The coverage did not specify which immunotherapy drug or protocol was involved, the age range of patients treated, or the location of the study. Those details were not included in the material available.
What to watch next: whether the full clinical data behind these figures is published, and whether regulators or treatment guidelines take up the approach for pediatric leukemia patients.